ENGI 150 case 3

ENGI 150 case 3 - ENGI 150 Case III: Drug Delivery Fall...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
ENGI 150 Fall 2009 Case III: Drug Delivery Alzheimer’s disease (AD) is a neurodegenerative disease of unknown origin that affects 5% of all Americans between ages 65-74 and may affect nearly half of those age 85 and older (National Institutes of Health). The definitive diagnosis of AD is made by finding microscopic plaques and protein tangles within the brain tissue of an affected individual (typically post-mortem); thus, in reality, the diagnosis is primarily made based on symptoms. AD typically begins as mild forgetfulness (names, places, etc.) but progresses to a point where the affected individuals are unable to perform daily activities or care for themselves. In many cases, one of the key signs that the disease has progressed is when the patient is unable to correctly take prescription medications, often forgetting whether a drug was taken, which can lead to dangerous overdoses or drug levels below therapeutic ranges. At present, AD is not curable. There are drugs that slow the progression of AD. One of the most widely used of these drugs is donepezil, an acetylcholinesterase inhibitor marketed by Pfizer under the trade name Aricept. Currently, Aricept is given once per
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 03/11/2010 for the course ENGI 150 taught by Professor Annsaterbak during the Fall '08 term at Rice.

Page1 / 2

ENGI 150 case 3 - ENGI 150 Case III: Drug Delivery Fall...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online